Therapieansätze bei Myositis

Zusammenfassung

Die Evidenzlage zur Therapie der Dermatomyositis, der Polymyositis und der Einschlusskörpermyositis ist niedrig, es gibt nur wenige randomisierte Doppelblindstudien. Empfohlen werden bei allen Erkrankungen Immunsuppressiva, Unterschiede in Evidenz und Wirkung werden zusammengefasst.

Summary

Evidence for treatment of dermatomyositis, polymyositis and inclusion body myositis is low. In literature there are only a few double-blind, randomised studies available. Recommendations include immunosuppressive agents, differences in evidence and efficacy of their use in dermatomyositis, polymyositis and inclusion body myositis are summarized.

Schlüsselwörter

Dermatomyositis - Polymyositis - Einschlusskörpermyositis - Immunsuppressiva

Keywords

Dermatomyositis - polymyositis - inclusion body myositis - immunosuppressive agents

• Literatur

• 1 Leitlinien der DGN – Myositiden, federführend Prof. Dr. H. Wiendl. www.dgn.org/inhalte-kapitel/474-leitlinien-der-dgn-myositiden.html
• 2 Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012; 24: 635-641.
• 3 Hoes JN, Jacobs JW, Boers M. et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66 (12) 1560-1567.
• 4 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012; 8: CD003643.
• 5 Oddis CV, Reed AM, Aggarwal R. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2012 doi: DOI: 10.1002/art.37754 [Epub ahead of print]